We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Antibiotics Offer No Advantage in Sinusitis Treatment

By HospiMedica International staff writers
Posted on 01 Mar 2012
A new study suggests that there is no clinically meaningful reason for prescribing antibiotics to treat acute rhinosinusitis.

Researchers at Washington University (St. More...
Louis, MO, USA) conducted a randomized, placebo-controlled trial of 166 adults (36% male; 78% Caucasian) with uncomplicated, acute rhinosinusitis to determine the incremental effect of amoxicillin treatment compared to symptomatic treatments. The patients were randomized to a 10-day course of amoxicillin (85 patients) or placebo (81 patients), administered in three doses per day. All patients received a 5-7 day supply of symptomatic treatments for pain, fever, cough, and nasal congestion to use as needed. The main outcome measure was improvement in disease-specific quality of life after 3 to 4 days of treatment; secondary outcomes included the patient's retrospective assessment of change in sinus symptoms and functional status, recurrence or relapse, and satisfaction with and adverse effects of treatment.

The results showed that the there was no significant difference between groups on day 3 and on day 10, but there was one on day 7 in favor of amoxicillin. There was no statistically significant difference in reported symptom improvement at day 3 or at day 10, whereas at day 7 more participants treated with amoxicillin reported symptom improvement (74% versus 56%, respectively), which was evident in nasal obstruction as recorded by a doctor. No between-group differences were found for any other secondary outcomes, and no serious adverse events occurred in either group. The study was published in the February 15, 2012, issue of the Journal of the American Medical Association (JAMA).

“There is now a considerable body of evidence from clinical trials conducted in the primary care setting that antibiotics provide little if any benefit for patients with clinically diagnosed acute rhinosinusitis,” concluded lead author Jay Piccirillo, MD, and colleagues, adding that their study “provides further evidence for what we've really suspected for a long time.”

Rhinosinusitis is an inflammation of the paranasal sinuses, which may be due to infection, allergy, or autoimmune issues. Most cases are due to a viral infection and resolve over the course of 10 days. The vast majority of cases of sinusitis are caused by viruses and will therefore resolve without antibiotics; however, if symptoms do not resolve within 10 days, amoxicillin is a reasonable antibiotic to use first for treatment, with added clavulanate being indicated when the patient's symptoms do not improve on amoxicillin alone.

Related Links:
Washington University


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.